Our main findings in acromegaly compared with NFPA were: (1) increased CBT in the proximal femur in patients with active disease; (2) a decline in CBT in the femoral neck following treatment; (3) enhanced femoral hip dimensions that were unmodified after treatment; and (4) interactions between GH and IGF‐1 levels and cortical thickness in patients with active disease that were not present at follow‐up. This evidence concerns the gene GH1 and acromegaly.